Skip to main content
Download PDF
- Main
Statins to mitigate cardiotoxicity in breast cancer patients treated with anthracyclines and/or trastuzumab: A systematic review and meta-analysis
- Obasi, Mary;
- Abovich, Arielle;
- Vo, Jacqueline B.;
- Gao, Yawen;
- Nohria, Anju;
- Asnani, Aarti;
- Partridge, Ann H.
The data associated with this publication are not available for this reason: N/A
Abstract
• Due to advances in treatment and early detection, nearly 90% of women with breast cancer are living at least 5 years following their diagnosis
o Living longer, there is increased risk for the development of longterm, late effects of cancer treatment
o Cardiotoxicity may arise either during or after breast cancer treatments such as anthracyclines and/or trastuzumab
• Recent evidence has suggested the potential for statin use, a lipidlowering drug, during treatment to mitigate the risk of cardiotoxicity in patients receiving cardiotoxic chemotherapy
• Research Question: Does statin use lower the risk of cardiotoxicity among breast cancer patients who receive treatment with anthracyclines and/or trastuzumab?